

Martina Biggioggero

List of Publications by Citations

Source: <https://exaly.com/author-pdf/732041/martina-biggioggero-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43
papers

1,196
citations

19
h-index

34
g-index

44
ext. papers

1,452
ext. citations

5.8
avg, IF

5.1
L-index

#	Paper	IF	Citations
43	Baricitinib for COVID-19: a suitable treatment?. <i>Lancet Infectious Diseases, The</i> , 2020 , 20, 1012-1013	25.5	137
42	The geoeidemiology of the antiphospholipid antibody syndrome. <i>Autoimmunity Reviews</i> , 2010 , 9, A299-304	3.4	124
41	Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 57-70	4.4	71
40	Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 1593-1603	4.4	64
39	Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. <i>Rheumatology</i> , 2014 , 53, 1664-8	3.9	60
38	Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 35-43	8.1	59
37	Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. <i>Arthritis Care and Research</i> , 2016 , 68, 432-9	4.7	57
36	Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug?. <i>Autoimmunity Reviews</i> , 2014 , 13, 1102-8	13.6	55
35	The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. <i>Autoimmunity Reviews</i> , 2017 , 16, 1185-1195	13.6	51
34	Sex and Management of Rheumatoid Arthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2019 , 56, 333-345	14.5	49
33	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 519-32	5.3	41
32	Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. <i>Drugs</i> , 2019 , 79, 1741-1755	12.1	31
31	Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. <i>Drug Development Research</i> , 2014 , 75 Suppl 1, S38-41	5.1	28
30	IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 900-4	2.4	28
29	Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. <i>Drugs in Context</i> , 2019 , 8, 212595	5.2	28
28	Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. <i>Clinical Rheumatology</i> , 2017 , 36, 1747-1755	3.9	23
27	Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis. <i>Arthritis Care and Research</i> , 2017 , 69, 867-874	4.7	23

26	Transforming growth factor beta1 in the pathogenesis of autoimmune congenital complete heart block: lesson from twins and triplets discordant for the disease. <i>Arthritis and Rheumatism</i> , 2006 , 54, 356-9		23
25	Type I interferon therapy and its role in autoimmunity. <i>Autoimmunity</i> , 2010 , 43, 248-54	3	22
24	Mavrimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 573-581	5.9	19
23	Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. <i>BioMed Research International</i> , 2014 , 2014, 831603	3	18
22	Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2013 , 44, 51-6	12.3	17
21	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 290	5.7	17
20	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register. <i>Joint Bone Spine</i> , 2014 , 81, 508-12	2.9	15
19	Spotlight on mavrimumab for the treatment of rheumatoid arthritis: evidence to date. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 211-223	4.4	14
18	Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e75	2.4	13
17	The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry. <i>Journal of International Medical Research</i> , 2016 , 44, 113-118	1.4	11
16	The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 1421-1429	4.4	10
15	A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 1969-1978	4.4	10
14	The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors. <i>BioMed Research International</i> , 2019 , 2019, 6107217	3	10
13	The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012 , 4, 213-23	3.8	9
12	The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. <i>BioMed Research International</i> , 2018 , 2018, 9460187	3	9
11	Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e5	2.4	8
10	The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 730-7	5.3	8
9	Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. <i>Modern Rheumatology</i> , 2018 , 28, 542-549	3.3	7

8	Structural integrity versus radiographic progression in rheumatoid arthritis. <i>RMD Open</i> , 2015 , 1, e000064.9	7
7	Sarilumab: patient-reported outcomes in rheumatoid arthritis. <i>Patient Related Outcome Measures</i> , 2018 , 9, 275-284	2.9 7
6	The challenging definition of naïve patient for biological drug use. <i>Autoimmunity Reviews</i> , 2015 , 14, 543-546	3.6 6
5	Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 561-571	5.1 3
4	Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 661-670	3.8 1
3	Mild cognitive impairment in psoriatic arthritis: Prevalence and associated factors. <i>Medicine (United States)</i> , 2021 , 100, e24833	1.8 0
2	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. <i>Clinical Rheumatology</i> , 2021 , 40, 4039-4047	3.9 0
1	Regulation of auto-antibody production by persisting auto-immune complexes on follicular dendritic cells. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, A38.1-A38	2.4